Citadel Advisors
ALXO icon

Citadel Advisors’s ALX Oncology ALXO Stock Holding History

Citadel Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,800
Closed -$52.9K – 12901
2025
Q4 		$52.9K Buy
+46,800
New +$70.9K ﹤0.01% 12005
2025
Q3 		– Sell
-11,700
Closed -$4.86K – 12673
2025
Q2 		$4.86K Sell
11,700
-25,200
-68% -$12.7K ﹤0.01% 12235
2025
Q1 		$23K Buy
36,900
+13,900
+60% +$16.7K ﹤0.01% 13039
2024
Q4 		$38.4K Buy
23,000
+16,000
+229% +$24.6K ﹤0.01% 12648
2024
Q3 		$12.7K Sell
7,000
-29,600
-81% -$110K ﹤0.01% 13088
2024
Q2 		$221K Buy
36,600
+28,200
+336% +$347K ﹤0.01% 9717
2024
Q1 		$93.7K Sell
8,400
-1,900
-18% -$26.7K ﹤0.01% 11449
2023
Q4 		$153K Buy
10,300
+9,800
+1,960% +$93K ﹤0.01% 10346
2023
Q3 		$2.4K Sell
500
-800
-62% -$4.34K ﹤0.01% 13723
2023
Q2 		$9.76K Buy
1,300
+1,100
+550% +$7.2K ﹤0.01% 13242
2023
Q1 		$904 Sell
200
-1,200
-86% -$9.09K ﹤0.01% 14401
2022
Q4 		$15.8K Buy
+1,400
New +$15.7K ﹤0.01% 13308
2021
Q4 		– Sell
-8,200
Closed -$606K – 13727
2021
Q3 		$606K Buy
8,200
+1,100
+15% +$73.3K ﹤0.01% 9393
2021
Q2 		$388K Buy
7,100
+2,100
+42% +$126K ﹤0.01% 10641
2021
Q1 		$369K Buy
+5,000
New +$393K ﹤0.01% 10366

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Citadel Advisors's ALXO Position: Q1 2026 in Review

Citadel Advisors sold out of ALX Oncology (ALXO) in Q1 2026, closing a stake of 56,732 shares — an estimated $108K sold.

Citadel Advisors first reported a position in ALXO in Q4 2020 and held it in 18 quarters. The position peaked at $24.4M in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Citadel Advisors reported no remaining ALX Oncology position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 56,732 ALX Oncology shares in Q1 2026, an estimated $108K.
  • Citadel Advisors first reported a position in ALX Oncology in Q4 2020 and held it in 18 quarters.
  • Citadel Advisors's ALX Oncology position peaked at $24.4M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.